Building on our findings and prior research [47] we challenged APL cells with VTX (BCL-2 inhibitor) and AZA (MCL-1/BCL-xL inhibitor), which also disrupts mitochondrial metabolism and enhances oxidative stress [37]. Here, BCL2L1 is linked to acute promyelocytic leukemia.